Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. The BSA-based method of dose calculation was adopted without adequate investigation of its ...

Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists? Drugs are to the medical oncologist what the scalpel is to the ...

Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody recognizing glypican-3 and CD3, is in phase I clinical trials. After a first-in-human clinical trial of an anti-CD28 agonist ...

Enhertu is a targeted medication used to treat specific HER2-positive or HER2-low cancers. Dosage is determined by body weight and the specific condition being treated. The following table shows ...